Moderna Q3 beats estimates on COVID sales and raises 2026 outlook
FROM THE WIRE · FINANCE.YAHOO.COM
Moderna MRNA posted third-quarter 2026 earnings per share (EPS) of 38 cents. The Zacks Consensus Estimate was a loss of $1.10 per share. In the year-ago period, the company incurred a loss of 51 cents. Total revenues climbed 29.2% year over year to $1.31 billion, surpassing the…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishResults above expectations and a raised outlook lift the stock, with impact limited to a single issuer.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Moderna posted third-quarter 2026 EPS of 38 cents, versus an expected loss of $1.10 per share.
- 02Total revenues rose 29.2% to $1.31 billion, driven by higher international COVID-19 vaccine sales.
- 03Shares rose in pre-market trading on Friday after better-than-expected results and raised sales guidance.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets